<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: For selected patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD) and/or early esophageal <z:e sem="disease" ids="C0007137,C0751688" disease_type="Neoplastic Process" abbrv="">squamous cell cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>), endoscopic therapy represents a nonsurgical treatment option </plain></SENT>
<SENT sid="1" pm="."><plain>For widespread lesions, however, current endoscopic treatment modalities (eg, endoscopic resection, <z:chebi fb="17" ids="49474,49475">argon</z:chebi> plasma coagulation, photodynamic therapy) are associated with considerable drawbacks, of which esophageal stricturing is the most significant </plain></SENT>
<SENT sid="2" pm="."><plain>Balloon-based radiofrequency (RF) ablation (HALO System) is a promising technology for endoscopic treatment of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and may also play a role in treating widespread HGD and early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVE: We describe a case report of balloon-based RF ablation for HGD and early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>DESIGN: Case report </plain></SENT>
<SENT sid="5" pm="."><plain>SETTING: Tertiary care institution, Academic Medical Center, Amsterdam, The Netherlands </plain></SENT>
<SENT sid="6" pm="."><plain>PATIENT: A 66-year-old male with a 35-mm large, flat-type <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> with surrounding HGD </plain></SENT>
<SENT sid="7" pm="."><plain>INTERVENTION: Balloon-based RF ablation (HALO System) </plain></SENT>
<SENT sid="8" pm="."><plain>MAIN OUTCOME MEASUREMENTS: Endoscopic and histological eradication of HGD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>, and adverse events </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: RF ablation resulted in complete endoscopic and histological eradication of HGD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> without adverse events such as <z:hpo ids='HP_0002015'>dysphagia</z:hpo> or <z:mp ids='MP_0003276'>esophageal narrowing</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>LIMITATIONS: Single patient report, limited follow-up </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: This is the first report of balloon-based RF ablation for esophageal HGD and early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>The treatment resulted in complete eradication of a 35-mm flat <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> with no adverse events </plain></SENT>
<SENT sid="13" pm="."><plain>This suggests that this ablation technique deserves further study for the management of widespread HGD or flat-type <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> </plain></SENT>
</text></document>